Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.06.2013 | short review | Ausgabe 2/2013

memo - Magazine of European Medical Oncology 2/2013

New developments in acute graft-versus-host disease

memo - Magazine of European Medical Oncology > Ausgabe 2/2013
Hildegard T. Greinix, MD Margit Mitterbauer, MD Werner Rabitsch, MD Nina Worel, MD Ulrike Just, MD Robert Knobler, MD Peter Kalhs


Allogeneic hematopoietic cell transplantation (HCT) is a well-established curative treatment option for selected patients with hematologic and oncologic diseases. Acute graft-versus-host disease (GvHD) has remained a serious complication of HCT and is associated with high morbidity and mortality especially in patients not responding to first-line therapy with corticosteroids. So far, no standard for salvage therapy of acute corticosteroid-refractory GvHD has been established worldwide. Use of extracorporeal photopheresis results in high response rates, has a steroid-sparing effect and is associated with improved patients’ survival.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Über diesen Artikel

Weitere Artikel der Ausgabe 2/2013

memo - Magazine of European Medical Oncology 2/2013 Zur Ausgabe